GlobeNewswire·Jan 26, 2026, 7:00 AM ET

Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026

NERV

Minerva Neurosciences, Inc. will host a virtual key opinion leader event on February 3, 2026, at 10:30 AM ET to discuss negative symptoms of schizophrenia.
Featured speakers include Gregory Strauss, PhD, from the University of Georgia, and Brian Kirkpatrick, MD, MSPH, from the University of Arkansas for Medical Sciences.
The event will address patient burdens, current assessment challenges, and how Minerva's upcoming Phase 3 trial of roluperidone aims to meet regulatory requirements.
No antipsychotic drug is currently approved specifically for negative symptoms, which remain an unmet medical need despite existing treatments addressing positive symptoms.
Minerva plans to initiate a confirmatory Phase 3 trial in 2026 using a novel protocol aligned with FDA guidelines established after a 2024 public meeting.
Approximately 50% to 60% of schizophrenia patients experience primary negative symptoms, which are debilitating and do not respond to standard antipsychotics.
Gregory Strauss directs the Clinical Affective Neuroscience Laboratory at the University of Georgia and has published over 275 papers with more than $82 million in grant funding.
Brian Kirkpatrick co-chaired the NIMH-sponsored Consensus Development Conference on Negative Symptoms and holds the John Emmett Peters Endowed Chair in Psychiatry at UAMS.
The virtual session will include a live question and answer period following the formal presentations.
Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, including roluperidone.
The press release includes forward-looking statements regarding trial timelines, outcomes, and regulatory approval risks subject to various uncertainties.